Who Should Receive Biologic Therapy for IBD?: The Rationale for the Application of a Personalized Approach

• Autores: Jennifer Jones, Juan Nicolás Peña Sánchez
• Localización: Gastroenterology clinics of North America, ISSN 0889-8553, Vol. 43, Nº. 3, 2014 (Ejemplar dedicado a: Biologics in Inflammatory Bowel Disease), págs. 425-440
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • The therapeutic approach in inflammatory bowel disease has evolved to target end-organ inflammation to heal intestinal mucosa and avoid structural damage. Objective therapeutic monitoring is required to achieve this goal. Earlier intervention with biologic therapy has been shown, indirectly, to be associated with higher clinical response and remission rates. A personalized approach to risk stratification with consideration of key clinical factors and inflammatory biomarker concentrations is recommended when deciding whether or not to start a patient on biologic therapy.